Poolbeg's Jeremy Skillington: "the results are as good as we hoped for"

Poolbeg #POLB CEO Jeremy Skillington talks to Vox Markets about the significance of the latest trial results for its flagship POLB 001 treatment for severe respiratory illness, and the drug's potentially significant role in delivering the new wave of cell-therapy cancer treatments.

To read the full RNS click here